Article Type : Original Articles
Authors : Yoichi Robertus Fujii
Keywords : microRNA; Quantum miRNA language; Artificial intelligence; CAD; CVD; Atherosclerosis; pacemaker
Background: Noninvasive microRNA (miRNA) biomarker panels
have been investigated in plenty of human diseases. In addition, using data
from the miRNA panel, many therapeutic target genes in coronary artery disease
(CAD) have been shown in silico. To further elucidate the integrated molecular
mechanism of CAD, which is also a metabolic disease, the quantum miRNA language
with artificial intelligence (MIRAI) was used and the etiology was preciously
simulated and statistically validated.
Methods: Data of miRNA panels in serum or plasma of patients
with CAD was extracted from the database. A miRNA entangling target sorter
(METS) with MIRAI, a bioinformatic algorithm based on quantum theory, was used
to analyze etiology in CAD as described previously.
Result: Two biological processes involved in CAD therapeutic
targets: 1) cardiac pacemakers and 2) inflammation of the intima in the
arteries. Hyperpolarization activated cyclic nucleotide gated potassium channel
4 (HCN4) and potassium voltage-gated channel subfamily H member 2 (KCNH2) were
increased by down regulation of the miR-133b hub. Cell cycle related proteins,
cyclin D1 (CCND1), cyclin D3 (CCND3), cyclin E1 (CCNE1) and cyclin-dependent
kinase 6 (CDK6) were enhanced by down regulation of the miR-424-5p hub.
Further, hypoxia inducible factor 1 subunit alpha (HIF1A) was also increased by
down regulation of the miR-424-5p hub. An area under the curve (AUC) of these
CAD therapeutic targets was 97.19% (accuracy: 94.4, precision: 99.04).
Conclusion: For the first time, we found a CAD therapeutic
target for a cardiac pacemaker. High levels of HCN4 expression increase funny
currents (If) and rapid spontaneous pulsations that can cause arrhythmia.
Increased KCNH2 is related with ventricular fibrillation through increased IKr
current, a major cause of sudden cardiac death. The other was the target of
atherosclerosis. Activation of cell cycle-related proteins in G1/S phase was
implicated in the proliferation of endothelial and smooth muscle cells. Further,
HIF1A augmentation is involved in macrophage proliferation, including
incorporation of oxidized low-density lipoprotein (oxLDL) into atherogenic
hypoxic lesions. Two different etiologies occurred simultaneously in different
lesions. Therefore, miR-133b and miR-424-5p mimics may be potential CAD
prophylaxis candidates as state-of-the-art treatments. MIRAI is a useful tool
for decoding layered-miRNA codes.
Coronary artery disease (CAD) mechanically
involves the narrowing of coronary arteries and the restricting of blood flow
to the heart, and results in cardiovascular disease (CVD), such as angina
pectoris, myocardial infarction (MI) or sudden death. The prevalence of CVD in
the United State of America (USA) was seriously an estimated 126.9 million
adults over 20 years old (49.2% overall population) in 2018 data [1]. CAD
includes acute coronary syndrome (ACS) subtypes as unstable angina (UA), acute
myocardial infarction (MI) with ST-segment elevation (STEMI), and MI without ST
elevation (NSTEMI) and stable CAD. The risk factors of CAD are smoking, low
physical activity, high body mass index (BMI), high calorie diet, high blood
pressure, high blood lipids, glycemia, genetic factors and infections, etc.
Protein biomarkers, such as natriuretic peptides, soluble suppression of
tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15),
high-sensitivity cardiac troponins (hs-cTn), C-reactive protein (CRP), interleukin
6 (IL-6), and myeloperoxidase, etc., have been used for patients of stable CAD
[2]. In the case of ACS, cardiac troponin T (CTnT), cardiac troponin I (CTnI),
creatine kinase muscle/brain subtype (CK-MB) has been used [3]. These
biomarkers are well known to have some limitations, such as slow first
appearance and increasing of chronic kidney disease (CDK). Therefore, sudden
death by CAD is not easy for early accurate diagnosis with current
histopathologic technology. It is well known that CAD is caused by
atherosclerosis and atherosclerosis is driven by a chronic inflammatory milieu
that induces plaque development with accumulation of oxidized low-density
lipoprotein (oxLDL) into macrophages (oxLDL-macrophages) and endothelial cells
[4]. Despite these data about the mechanisms of CAD, the impact of
atherosclerosis has not yet cleared by the histochemical and immunological
pathophysiology because atherosclerosis is a complex multifactorial disease.
The patients with increases in the base-line levels of CRP as the inflammation
index have significantly been correlated with acute CAD, and anti-cholesterol
agent, statin has decreased CVD risk but not changed in the LDL profile of
patients [5]. In addition, by double-blind trial of canakinumab, anti-interleukin
1? (IL-1?), recurrent risk of CVD has been observed to reduce in patients with
previous MI and high CRP level of >2 mg/L [6]. Therefore, residual
heightened inflammation might be associated with risk of CDA but oxLDL
reduction has not curtained to contribute for CAD risk [7]. As an evidence, the
foam cells in the arterial intima absorb LDL; however, the molecular mechanisms
controlling atherogenesis are still not fully understood [8]. Because
increasing rates of LDL transcytosis across endothelial cells remain unclear
during hypercholesterolaemia [9]. Processes of modified LDL particles are
multiple, such as proteolysis, phospholipolysis, oxidation, hydrolysis and
proteoglycan interactions. Although the modified LDL particles can trigger
proinflammatory reactions, it is uncertain whether activation of arterial
intimal cells or inflammation via the intima injury is the first event. A
VLDL-ligand ApoE-knockout (KO) mice with high-fat diet is commonly used to
examine atherosclerotic events; however, suppression of polyunsaturated fatty
acids (PUFAs) with high fat diet has not provoked ApoE-deficiency mediated
atherosclerosis plaque formation in the double KO mouse (fads2-/- x apoe-/-)
model experiment [10-12]. As the similar results were obtained in LDL receptor
deficient double KO mice, ?6-fatty acid desaturase (fads2) related
?6/?3-polyunsaturated fatty acids would be more closely implicated in the
plaque formation than LDL. PUFA is a source of precursors for immunomodulators,
such as prostaglandin and leukotriene [13]. Even murine model experiments, the
data suggests that inflammation would be the first cause of atherosclerosis.
The comprehensive results in the dietary studies of atherosclerosis suggest
that LDL particles in histopathological data of atherosclerosis might have not
been corresponding to the cause of disease as the amyloid plaque hypothesis in
Alzheimer’s disease. MiRNA has an important role for controlling of the
pathogenesis in CAD [14]. Cholesterol homeostasis, reverse cholesterol transport,
plaque initiation and progression, plaque rupture and plaque neovascularisation
related miRNAs in atherosclerosis have been preciously documented in several
reviews [14-20]. Circulating miRNAs in the plasma or serum have been available
for non-invasive and early diagnosis to prevent sudden death by CAD [18]. But
the key of the CAD aetiology related with miRNAs remains unclear. A
bioinformatic technique, miRNA entangling target sorting (METS) analysis with
quantum miRNA language plus artificial intelligence (MIRAI) has revealed the
cancer aetiology and therapeutic targets of breast, lung, colorectal,
pancreatic, esophageal, gastric and liver cancers [21-24]. Etiologies of
infectious diseases, such as hepatitis B and C viruses (HBV and HCV), human
immunodeficiency virus (HIV-1) and severe acute respiratory syndrome human
coronavirus 2 (SARS-CoV-2), have also been computed by METS with MIRAI [24-28].
These data suggested that miRNA biomarker panels in diagnosis is useful for
pathophysiologic search to investigate therapeutic targets. Plenty of
successful METS analysis data showed that miRNA gene code of human could be
decoded by an algorithm of quantum miRNA language, and it is very distinct from
protein gene code because miRNA gene code follows the basis of quantum
mechanics [29]. Since the RNA wave 2000 model has been enough validated by
previous lots of reports; 1) the miRNA gene is a mobile genetic element that
induces transcriptional and posttranslational silencing through network
processes, 2) the RNA information supplied by miRNA genes expands to
intracellular, intercellular, intraorgan, interorgan, intraspecies, and
interspecies under the life cycles in the global environment, 3) mobile miRNAs
self-proliferate and 4) cell contain resident and genomic miRNAs, most of all
biological processes including atherosclerosis are controlled by miRNAs [29].
In this paper, the etiology of coronary artery disease (CAD) from circulating
profiles in plasma/serum was investigated by using METS/MIRAI. The factor of
cardiac pacemaker in CAD was firstly found as a cause of CAD and the
controversial data of atherosclerosis in CVD was discussed.
Databases
Google Scholar
(https://scholar.google.co.jp) were firstly used for data extraction from miRNA
panels and miRNA profiles in the plasma or serum. Total information contents
were 181,427 in CAD, 157,794 in atherosclerosis and 2,716,846 in cardiovascular
disease. The gene function of protein was searched by GeneCards. Protein
ontology was investigated by GO enrichment analysis in Geneontology. Data of
multi-targets to a miRNA and multi-miRNAs to a target were obtained from
TargetScan Human 7.2, DIANA-TarBase and miRTarBase Ver. 8.0 or mirtarbase data
for miRTarBase release 6.1, which was re-built up by Excel file of the package
in the GitHub. Protein/protein interaction search and cluster analysis were
performed by using STRING Ver. 11.0. The RNA secondary structures of the
artificial stem loop were computed by RNA Fold.
METS network analysis
The METS network
analysis was performed with MIRAI from the miRNA memory package (MMP), of which
data is statistically extracted from clinical miRNA biomarkers and miRNA
profiles as previously described [24-26, 30-32]. Data mining about miRNA panels
was performed by 1) data from serum or the plasma, 2) cleared in expression
levels of up- and down-regulation, 3) data was statistically analysed by
receiver operating characteristic (ROC) and the cut off value of an area under
the curve (AUC) about biomarker profiling is 0.7 (Table 1).
As the quantum miRNA
language, single nexus score (SNS) and double nexus score (DNS) in the matrix
algorithm were computed as previously described [29]. The values of electric
field tangent score (EFT) were computed in microRNA memory package (MMP) from
miRNA biomarker panels of CAD to use weighting of the DNS value as described
previously [33].
MIRAI
AI was used with the quantum miRNA language for METS analysis as previously described. The area under the curve (AUC) in receiver operating characteristic (ROC), accuracy, and precision were calculated as the percentage by using previous integrated data pool [24].
Table 1: Table 1: MMP from plasma/serum data in CAD.
miRNA |
Level |
Source |
SNS |
AUC data |
Reference no. |
|
Stable CAD |
Acute CAD |
|||||
miR-133b |
down |
Plasma |
3 |
0.800 |
|
34 |
miR-499a-5p |
up |
Plasma |
5 |
0.713 |
|
35 |
miR-765 |
up |
Plasma |
11 |
0.959 |
0.972 |
36 |
miR-149-5p |
down |
Plasma |
4 |
0.938 |
0.977 |
|
miR-29b-3p |
down |
Serum |
4 |
0.930 |
|
37 |
miR-208a-3p |
up |
Serum |
5 |
0.847 |
|
|
miR-215-5p |
up |
Serum |
4 |
0.913 |
|
|
miR-424-5p |
down |
Plasma |
4 |
0.919 |
0.960 |
38, 39 |
miR-502-5p |
up |
Serum |
5 |
0.867 |
|
37 |
Bold: hub miRNAs |
Table 2: Validation of CAD etiology with MIRAI.
|
CAD |
AUC |
97.19 |
Accuracy |
94.40 |
Precision |
99.04 |
Recall |
94.50 |
F value |
96.71 |
Quantum energy levels
of CAD
Energy levels of DNS and EFT were computed and depicted by using MMPs of CAD. Unique radar chart was observed according to weighting of EFT values. Levels of DNS and EFT in the hub miRNAs were 12 and 439875.5 in AD. The hub miRNAs experienced the high value of electric field intensity; therefore, CAD-related hub miRNA forced high electric intensity (EFT value). On the other hand, DNS of the hub miRNA in CAD was quite low because the quantum energy layers of DNS for the matrix of MMP in CAD was shown as the quantum core region (QCR) of 10-20. But the frequency of DNS was high in the QCR of 0-20. It suggests that CAD-related miRNAs are stable in quantum state but electrically active (Figure 1).
Figure 1:
Quantum energy levels of miRNAs in CAD. The DNS and EFT values of MMP for CAD
were depicted in the radar chart (A). The matrix of MMP was shown as the DNS
values and the quantum core region (QCR) layers were determined (B).
Frequencies of the DNS value in CAD in layers of QCR, 0-20, 21-40 and 41-60
were represented (C). QCR containing a DNS of two hub miRNAs were shown as
arrows (amber).
MMPs of CAD
Nine miRNAs were
extracted as an MMP of coronary artery disease (CAD) from circulating profiles
in plasma/serumand upon a meta-analysis [34-39]. Four miRNAs, miR-133b,
miR-149-5p, miR-29b-3p and miR-424-5p have been down regulated, and five
miRNAs, miR-449a-5p, miR-765, miR-208a-3p, miR-215-5p and miR-502-5p were up
regulated. AUC on CAD diagnosis of 8 miRNAs was >0.8 in stable CAD vs.
non-coronary artery (NCA) people except for miR-449a-5p (AUC: 0.713). Three
miRNAs, miR-765, miR-149-5p and miR-424-5p were common ones of stable and
unstable CAD with the AUC of >0.96. While the seed of miR-133a-3p has the
complete same nucleic acid sequences in miR-133b except for the 5’ end (g/a),
miR-133a-3p and miR-449a-5p, which were unregulated in the tissues, have shown
as the biomarker of sudden cardiac death by using with samples of autopsy
cardiomyocyte tissues [40]. Further, miR-133b (down regulation) has been as
circulating biomarker in early prediction of CAD [34]. When METS computing of
CAD biomarker was performed, the GO analysis of miRNA targets showed two
possible biological processes: 1) SA node cell to atrial cardiac muscle cell
signaling (GO: 0086018), 2) epithelial cell maturation (GO: 0002070). The data
indicated two separate biological pathways. The former would be implicated in
heart pacemaker and the latter would be associated to inflammation followed by
atherosclerosis. Therefore, the etiological investigation of CAD by METS was
involved into two parts of the organ, the heart and the coronary arteries. It
is suggested that two different etiologies are simultaneously occurring in two
different lesions (Figure 2).
The cardiac pacemaker
in stable CAD
MiR-133b has been statistically used as a biomarker of stable CAD. Heart rate is initiated by spontaneous depolarization of the sinoatrial node as pacemaker cells [41]. An increased heart rate has been associated with coronary atherosclerosis in animal models and patients [42]. Although it has been thought that an elevated heart rate would be due to several stresses, such as increasing plaque formation in the arterial endothelial walls, oxidative stress and inflammation of the coronary artery, our METS analysis showed that hyperpolarization activated cyclic nucleotide gated potassium channel 4 (HCN4) and potassium voltage-gated channel subfamily H member 2 (KCNH2) were increased by down regulation of miR-133b hub along with miR-6511b-5p, miR-4748 plus miR-557, and with miR-7-5p. Calcium voltage-gated channel auxiliary subunit gamma 7 (CACNG7) was suppressed by up regulation of miR-765 in combination with miR-7-5p.
Figure 2: Network diagram of METS computer simulation in MMP of CAD. The linkage among protein clusters and miRNA/miRNA was presented by METS. miRNAs and proteins in red: up regulation, in blue: down regulation. Small circles in blue are the hub miRNAs. Large circles in amber (pacemaker) and in green (inflammation) are presented as GO protein cluster functions.
In mouse embryonic stem
cell-derived cardiomyocytes, HCN4-overexpression have increased funny currents
(If) and rapid spontaneous beating [43]. Since elevating of If have augmented
pacemaker activity of the sinoatrial node and heart rate in mice, HCN4
increasing by miR-133b hub down regulation would be implicated in heart rate
elevating in CAD. On the contrary, KCNH2 (the human ether-a-go-go-related
channel, hERG) overexpression has increased IKr currents and accelerated
re-entry frequency or fibrillation in neonatal rat ventricular myocyte
monolayers but been undetectable pacing frequencies [44,45]. It is suggested
that KCNH2 elevating by miR-133b hub down regulation would be related to
ventricular fibrillation, which causes a major cause of sudden cardiac death.
As arterial and ventricular myocytes in ischemic cardiomyopathy have reduced
expression of CACNG7, down regulation of CACNG7 by up regulation of miR-765 may
be a cause of CAD have showed that heart failure-associated miRNAs target to
the sinoatrial node (SAN) automaticity-associated proteins, HCN1, HCN4 and
solute carrier family 8 member A1 (SLC8A1) from comprehensive transcriptomic
analysis of pure human SAN pacemaker tissue. This report from the human tissue
with heart failure strongly supported our data in the etiologic analysis with
METS/MIRAI from circulating miRNA panel [46,47].
Inflammation in the
arterial intima
A biomarker of
miR-424-5p was used as both acute and stable CAD states. Cell cycle related
proteins, cyclin D1 (CCND1), cyclin D3 (CCND3), cyclin E1 (CCNE1) and
cyclin-dependent kinase 6 (CDK6) were enhanced. For details, CDK6 was up
regulated by miRNA hub miR-29b-3p or miR-424-5p down regulation long with
miR-34a-5p, miR-449a, miR-124-3p, miR-16-5p, miR-107 and miR-195-5p. CCNE1 was
increased by down regulation of miR-424-5p with miR-16-5p and miR-15a-5p. CCND3
and CCND1 were enhanced by miR-424-5p with miR-16-5p, and with let-7b-5p,
miR-34a-5p, miR-503-5p, miR-20a-5p, miR-17-5p, miR-16-5p, miR-15a-5p,
miR-302a-5p and miR-195-5p, respectively. Cell migration of atherosclerosis
occurs at G1/S phase of the cell cycle, and CCND1 plus CCND3 controlled by CDK6
and CCNE1 are implicated in G1/S transition has showed in their bioinformatics
analysis that CDK6 is a key regulator of atherosclerosis. Since human
endothelial cells and vascular smooth muscle cells produce proinflammatory
mediators in atherosclerosis, augmentation of cell cycle related proteins would
progress angiogenic inflammation with proinflammatory cytokines. Fibroblast
growth factor receptor 1 (FGFR1) was increased by miR-424-5p down regulation
with miR-214-3p. FGFR1 expression of endothelial cells in patients with
atherosclerosis has been decreased [48-50]. In the mouse apoE-/- model,
atherosclerotic lesions have expressed FGFR1 and activated FGF/FGFR1 signalling
pathways that promotes atherosclerosis development [51]. When human carotid
atherosclerotic plaques were analysed, expression of basic fibroblast growth factor
(bFGF) and FGFR1 has been increased in vascular smooth muscle cells (VSMCs)
[52]. Both bFGF and FGF-2 has been detected in human atherosclerotic plaques
and been synthesized by endothelial cells, vascular smooth muscle cells and
macrophages, and FGFR1 been implicated in cell growth of endothelial and
vascular smooth muscle cells [53,54]. These data strongly supported our
computer simulation data from miRNA biomarker panels that FGFR1 elevation by
miR-424 hub down regulation would induce CAD through atherosclerosis. Foam cell
formation is initiated by accumulation of oxidized low-density lipoprotein
(oxLDL) into macrophages, and its dysfunction with endothelial cells at
lesion-prone sites in the walls of arteries causes inflammation of the arterial
intima [9]. The thickness increasing of the arterial walls by inflammation
induces hypoxic conditions in the atherosclerotic lesion; therefore,
hypoxia-inducible factor 1 alpha (HIF1A) is related with atherosclerosis. HIF1A
expression has been a major factor of angiogenesis in above cellular response
in the hypoxic legions [55]. HIF1A was augmented by down regulation of
miR-424-5p with miR-20a-5p, miR-18a-5p, miR-17-5p, miR-107, miR-106b-5p,
miR-519c-3p and miR-27a-3p. Since hypoxia has enhanced lipid uptake into macrophages,
up regulation of HIF1A would be deeply implicated in CAD progression [56].
Furthermore, HIF1A molecule is modulated by phosphorylation with extracellular
signal-regulated kinase 1/2 (ERK1/2), mitogen-activated protein kinase (MAPK)
and protein kinase B (PKT) [57]. However, in our analysis, MAP2K1 as the ERK
activated kinase was increased by suppression of miR-424-5p with miR-34a-5p and
miR-181a-5p. Therefore, up regulation of MAP2K1 would be related with CAD
progression via ERK1/2 activation. In the case of a mouse model, ERK1/2, MAPK
and AKT has proliferated oxLDL incorporated-macrophages (oxLDL-macrophages) and
CDKN1A (p21cip) inhibition by short interfering RNA (siRNA) has suppressed
proliferation of oxLDL-macrophages via granulocyte/macrophage
colony-stimulating factor (GM-CSF) suppression [58]. Virtually, CDKN1A was
suppressed by up regulation of miR-208-3p long with miR-93-5p, miR-20b-5p,
miR-20a-5p, miR-17-5p, miR-106a-5p, miR-106b-5p, miR-519d-5p, miR-145-5p and
miR-96-5p; therefore, suppression of CDNK1A would be cooperated with increasing
of oxLDL-macrophages in the atherosclerotic lesion. However, the oxLDL
particles can trigger proinflammatory reactions and canakinumab,
anti-interleukin 1? (IL-1?) reduced recurrent risk of patients in CVD [6]. In
addition, as obesity and overweight induces a serious inflammatory condition
that contributes to atherosclerosis through increasing of chemoattractant
macrophages, oxidative stress and abnormal lipid metabolism, hypertension and
sympathetic nerve activation, anti-inflammatory adipokines and weight
management decrease atherosclerotic risk [59,60]. Therefore, HIF1A increasing
expression may be related to proliferation of inflammatory macrophages in the
hypoxic regions of the arterial intima at first, then accumulation of oxLDL.
First-line treatment
of CAD
Medications for the
treatment of stable CAD are statin, beta blockers and aspirin in the evidence
rating of A (consistent, good-quality patient-oriented evidence) [61]. Although
statin treatment is a therapy of lipid-lowering to decrease LDL, inflammation might
be associated with risk of CDA but oxLDL reduction has not curtained to
contribute for CAD risk [7]. By using statin, many patients of
hypercholesterolemia can reduce LDL levels; however, statins have pleiotropic
effects, such as suppression of inflammation, inhibition of oxidative stress,
regulating angiogenesis and improvement of endothelial function [62,63].
Therefore, it is unknown whether decreasing risk of CAD is due to effect of
lowering LDL by stain or not, or combined effects. It has been shown from
meta-analysis that in the first two years after MI, beta blockers can double
the reduction in cardiovascular events compared with other antihypertensive
agents [64]. However, it has recently been reported that beta-blockers have
little or no effect on the short-term risk of a reinfarction and mortality
[65]. In further recent meta-analysis, beta blockers have not showed the
benefit for patients with stable CAD without prior MI or left ventricular
dysfunction to prevent cardiovascular disease [66]. The use of aspirin,
non-steroidal anti-inflammatory drugs (NSAIDs) is widely recommended for the
secondary prevention of atherosclerosis in all patients. Aspirin inhibits
cyclooxygenase 1 and 2, reducing prostaglandin and thromboxane-A production and
preventing platelet aggregation while aspirin also have pleiotropic effects
[67]. Further, aspirin is connected to increasing internal bleeding as the
harmful side effect that would outweigh its cardio protective properties in
some patients [68]. Therefore, recent randomized controlled trials have
challenged the primary prevention of atherosclerotic CVD and using
meta-analysis, in patients with percutaneous coronary intervention and
stenting, assigned to a strategy of early aspirin discontinuation vs. dual antiplatelet
therapy, the risk of death and ischemic events has not been significantly
different [69,70]. These data statistically indicate that the therapeutic
targeting of CAD would still be not enough to make strategy of precious
medicine treatment according to its pathophysiologic mechanisms. Thus, the
etiologic computer simulation of CAD from circulating profiles in plasma/serum
was useful for precious medicine to find new therapeutic targets.
Data validation and
network analysis
In our METS simulation
with AI, miR-133b down regulation was involved into arrhythmia and fibrillation
and miR-424-5p suppression was implicated in atherosclerosis. Data of CAD
showed 97.19% of AUC, 94.4% of accuracy, 99.04% of precision, 94.5% of recall
and 96.71% of F value (Table 2).
MiR-133b reduction has been observed in human infarcted tissues, which contributed to arrhythmogenesis [71]. MiR-424-5p has been found as a circulating biomarker of future acute MI prediction; however, mR-133b and miR-424-5p pathophysiologic protein targets for CAD have not yet been shown. Plenty of CAD therapeutic target genes have been outcome in silico by the integrated network analysis, such as homeobox A5 (HOXA5), HOXB5, HOXC6, HOXC8, HOXB7, collagen type I alpha 1 chain (COL1A1), CCND1, c-c motif chemokine ligand 2 (CCI2), haptoglobin (HP), twist family BHLH transcription factor 1 (TWIST1), smad family member 4 (SMAD4), toll like receptor 4 (TLR4), sp1 transcription factor (SP1), estrogen receptor 1 (ESR1), interferon regulatory factor 2 (IRF2), cell death inducing DFFA like effector B (CIDEB), prooplomelanocortin (POMC), and calreticulin (CALR) genes; however, with the software, for example, Gene Set Enrichment Analysis (GSEA) (http://software.broadinstitute.org/gsea/index.jsp), the relation among miRNAs is not computed at all and the statistical validation of the results has not been done. Additionally, by meta-analysis in 2021, caveolin 1 (CAV1) and heat shock transcription factor 2 (HSF2) genes have been extracted as the CAD therapeutic target; therefore, the results of more CAD therapeutic targets were complicated and the pinpointed therapeutic target for CAD has still been uncertain. It is the reason that a miRNA can direct to multi-protein mRNA 3’UTR, and a 3’UTR of mRNA is targeted to multi-miRNAs [72-78]. To solve this mathematical problem, algorithm between miRNA and miRNA interaction is needed with AI. On the other hand, as the matrix algorithm between multi-miRNAs based on the quantum miRNA language was used in our METS analysis with AI, above problem is cleared. Therefore, this is the first report statistically validated that HCN4 plus KCNH2, and cell cycle-related proteins plus HIF1A plus FGFR1 are the certain therapeutic target of heart pacemaker, and atherosclerosis for patients with CAD, respectively (Figure 3).
Figure 3: Therapeutic target miRNAs and proteins in CAD. Molecular mechanisms in CAD were depicted in right and left panels. Up regulated proteins and pathways were in red, down regulated miRNAs were in blue. An artificial stem loop is containing miR-133b and miR-424-5p mimics and both miRNA hub mimics may use for treatment of CAD.
Thus, an artificial
stem loop agent including miR-133b and miR-424-5p hub mimics may provide the
benefit for individuals with stable CAD. However, CAD pathogenic experiments
have been prepared from mouse or rat model except for human clinical miRNA
data. To remove rodent bias, statistically significant sample size in human was
still limited for more precious diagnosis and prediction of CAD. Further clinical
data with circulating miRNAs would be needed.
The
current systematic review and meta-analysis showed to challenge the treatment
of CAD with the first- and second-line drugs and it can reduce the risk of CAD.
There was no clear evidence of an association between CAD therapeutic agents
use and adverse cardiovascular outcomes. To further understand the CAD
therapeutic target, we used circulating miRNA biomarker panels. A therapeutic target
of CAD about cardiac pacemaker was firstly found in silico. HCN4, a potassium
channel in SAN, was up regulated by down regulation of miR-133b hub with
miR-6511b-5p, miR-4748 plus miR-557. Since HCN4 increasing induces funny
currents (If) and rapid spontaneous beating, augmentation of HCN4 levels may
evoke arrhythmia. Further, KCNH2, a potassium voltage-gated channel in
ventricular myocytes, was also increased by down regulation of miR-133b hub
with miR-7-5p. While KCNH2 up regulation increases IKr currents and then
re-entry frequency, KCNH2 enhancing may be implicated in ventricular
fibrillation that induces sudden cardiac death. Another therapeutic target of
CAD with atherosclerosis was secondarily found by METS analysis. Endothelial
and smooth muscle cells would be proliferated in the arterial intima by
acceleration cell cycle. G1/S phase-related proteins, CCND1, CCND3, CCNE1 and
CDK6 were up regulated by down regulation of miR-424-5p hub with miR-15 family.
In addition, HIF1A was augmented by down regulation of miR-424-5p hub.
Therefore, miR-133b and miR-424-5p mimics would be the possible CAD preventing
agent candidate as a state-of-the-art treatment. MIRAI is useful for decoding
layered-miRNA codes and finding therapeutic targets for human diseases.
The authors declare that there are no conflicts of interest.